Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Bionome Technology Limited currently manages 1 pending office action in the Biotechnology & Pharmaceuticals technology area. The portfolio's active prosecution is limited to 1 distinct examiner and 1 distinct art unit, which points to a focused technological interest. This suggests that the company is currently pursuing a specific biological or pharmaceutical advancement through an application.
The busiest examiner, ZHANG SPIERING, DONGXIU, handles 1 busiest examiner pending office action. As this figure is equal to the total of 1 pending office actions, this examiner is the individual currently assigned to the company's active matters. The prosecution strategy for Bionome Technology Limited must therefore be tailored to the specific expectations of this distinct examiner within their art unit.
With only the distinct art unit involved, there is no evidence of technical diversification in the current pending workload. The pending office action is the focus of the portfolio's active status at the USPTO. This concentration allows the practitioner to dedicate resources to resolving the matter with ZHANG SPIERING, DONGXIU without the distraction of other active cases in the Biotechnology & Pharmaceuticals sector.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ZHANG SPIERING, DONGXIU | 1 | 41.2% | +65.2% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17907219 | CONTROLLING THE GROWTH OF VEGETATION | ZHANG SPIERING, DONGXIU | 78d overdue |
| Art Unit | Apps |
|---|---|
| 1616 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17907219 | CONTROLLING THE GROWTH OF VEGETATION | ZHANG SPIERING, DONGXIU | 1616 | §103DP | Non-Final OA | 78d overdue | Pending | Sep 23, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialBionome Technology Limited has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Dongxiu Zhang Spiering has the most, with 1 of Bionome Technology Limited's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
